v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
OPERATING EXPENSES:    
Research and development $ 26,480 $ 30,880
General and administrative 16,424 18,736
Total operating expenses 42,904 49,616
Loss from operations: (42,904) (49,616)
OTHER INCOME (EXPENSE), NET:    
Fair value change of warrant liabilities 130,916 19,460
Benefit from R&D tax credit 2,477 8,448
Interest income 2,419 2,386
Interest expense (1,465) (1,124)
Foreign exchange (losses) gains (736) 2,133
Other income 484 803
Total other income, net 134,095 32,106
Income (loss) before income taxes 91,191 (17,510)
Income tax benefit (expense) 11 (354)
Net income (loss) $ 91,202 $ (17,864)
Net income (loss) per share attributable to ordinary shareholders: basic (in dollars per share) $ 0.71 $ (0.20)
Net income (loss) per share attributable to ordinary shareholders: diluted (in dollars per share) $ (0.30) $ (0.24)
Weighted average ordinary shares outstanding: basic (in shares) 110,064,581 89,192,252
Weighted average ordinary shares outstanding: diluted (in shares) 130,266,693 98,641,623
Other comprehensive income (loss):    
Foreign exchange translation adjustment $ (6) $ (117)
Comprehensive income (loss) $ 91,196 $ (17,981)